Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

KTTA vs ANRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Captures Overall Composite Edge (45.8 HOLD vs 42.1 HOLD), While KTTA Leads 3–1 on Growth & Valuation Pillars

ANRO Overall Winner 6-Pillar Tally: KTTA 3 – 1 ANRO (2 Tie) Matrix Metrics: KTTA 1 – 5 ANRO

As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (45.8/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 5–1 (led by Balance Sheet & Cash Flow), while KTTA wins 3–1 across the 6-pillar growth and valuation breakdown. KTTA trades at $0.48 (N/M Forward P/E, 0.0% operating margin) versus ANRO at $25.37 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ANRO earns the overall head-to-head edge with a stronger Unified Composite Score (45.8/100 HOLD vs. KTTA 42.1/100 HOLD) and 1.86β · 91% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ANRO is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KTTA vs ANRO
KTTA NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
TTM Revenue $486,559
Forward P/E N/M
Beta / 30D Vol 0.68β · 185% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.1%) with fading momentum, RSI 50
RSI-14: 49.6 · SMA20: $0.48 · SMA50: $0.47
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.37
-4.3% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.86β · 91% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.9%) with fading momentum, RSI 49
RSI-14: 48.5 · SMA20: $25.37 · SMA50: $25.58

6-Pillar Scorecard Institutional Category Breakdown (KTTA 3 – 1 ANRO)

Columns: Metric · KTTA · ANRO
1. Valuation Multiples KTTA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 36.3x N/M
2. Growth & Scale KTTA
Revenue Growth (YoY) +1498.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $486,559 N/A
Market Cap $17.7M $1.1B
3. Profitability & Quality Tie
Gross Margin -0.5% N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -88.8% -46.7%
4. Balance Sheet & Cash Flow ANRO
Cash Generation (TTM) -$18M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.31 Book/Sh · -88.8% ROE $301M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KTTA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 80.4% (8th %ile)
Put/Call OI Skew N/A 20.60x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KTTA (1) vs ANRO (5)
Institutional Metric KTTA ANRO Criterion Row Edge
Market Capitalization
Scale
$17.7M $1.1B Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+1498.1% +0.0% Higher Growth KTTA
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-88.8% -46.7% Higher ROE ANRO
52-Week Range Position
Momentum
11% ($0–$2) 52% ($13–$37) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
0.68β · 185% Vol 1.86β · 91% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite ANRO
Trailing 12M Revenue (USD)
Operating Scale
$486,559 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-0.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 36.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$18M ($1.31 Book/Sh · -88.8% ROE) -$80M ($301M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +6.76 pp
KTTA: +7.52% · ANRO: +14.28%
3M Horizon KTTA +24.8 pp
KTTA: -5.21% · ANRO: -30.01%
6M Horizon ANRO +51.15 pp
KTTA: -31.59% · ANRO: +19.56%
1Y Horizon ANRO +62.67 pp
KTTA: +0.59% · ANRO: +63.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KTTA vs ANRO. Trailing 12-month operating profitability (KTTA 0.0% vs ANRO 0.0%) and valuation multiples (KTTA N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

KTTA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$486,559
Gross Margin-0.5%
Op. Margin0.0%
ROE / Fwd P/E-88.8% · N/M
ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KTTA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
61d in phase · OBV DISTRIBUTION
Current IV 80.4%
IV Percentile 8th %ile
Put/Call OI Skew 20.60x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KTTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $17.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KTTA vs ANRO Key Questions & Quantitative Answers

As of Nov 20, 2026, Alto Neuroscience Inc. (ANRO) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (45.8/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 5–1 (led by Balance Sheet & Cash Flow), while KTTA wins 3–1 across the 6-pillar growth and valuation breakdown. KTTA trades at $0.48 (N/M Forward P/E, 0.0% operating margin) versus ANRO at $25.37 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ANRO earns the overall head-to-head edge with a stronger Unified Composite Score (45.8/100 HOLD vs. KTTA 42.1/100 HOLD) and 1.86β · 91% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ANRO is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KTTA leads the Growth & Scale pillar: KTTA posts +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, KTTA generates $486,559 in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, KTTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.

KTTA screens cheaper on headline valuation multiples. KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KTTA (-88.8% ROE) versus ANRO (-46.7% ROE) capital efficiency.

In options market volatility and institutional positioning, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk). By comparison, ANRO carries 80.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 20.60x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.86β · 91% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.